ArticleOncogene2004
Bone morphogenetic protein-5, -6 and -7 inhibit growth and induce apoptosis in human myeloma cells.
Article in Oncogene, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 128 citations in OpenAlex.
- Humanized Bone Model Identifies BMP6 as a Multifunctional Regulator in Myeloma Bone Disease.Biomolecules · 2025Article
- Transcriptional analysis of BMP2 and BMP6 in patients with newly diagnosed multiple myeloma.Oncology letters · 2025Article
- Bone morphogenetic proteins (BMPs) at the forefront of ocular diseases and therapeutics.Eye and vision (London, England) · 2025Review
- Age-related mesenchymal stromal cell senescence is associated with progression from MGUS to multiple myeloma.Leukemia · 2025Article
- The FGF/FGFR/c-Myc axis as a promising therapeutic target in multiple myeloma.Journal of experimental & clinical cancer research : CR · 2024Review
- A cell cycle centric view of tumour dormancy.British journal of cancer · 2023Review
- High concentrations of soluble endoglin can inhibit BMP9 signaling in non-endothelial cells.Scientific reports · 2023Article
- FKBP12 is a major regulator of ALK2 activity in multiple myeloma cells.Cell communication and signaling : CCS · 2023Article
- Morphogens and growth factor signalling in the myeloma bone-lining niche.Cellular and molecular life sciences : CMLS · 2021Review
- BMP5 silencing inhibits chondrocyte senescence and apoptosis as well as osteoarthritis progression in mice.Aging · 2021Article
- Receptor binding competition: A paradigm for regulating TGF-β family action.Cytokine & growth factor reviews · 2021Review
- Activins as Dual Specificity TGF-β Family Molecules: SMAD-Activation via Activin- and BMP-Type 1 Receptors.Biomolecules · 2020Article
- A Multi-Omics Analysis of Bone Morphogenetic Protein 5 (Biomedicines · 2020Article
- Bone Morphogenetic Protein 4 Gene Therapy in Mice Inhibits Myeloma Tumor Growth, But Has a Negative Impact on Bone.JBMR plus · 2020Article
- Transcriptomic profiling of the myeloma bone-lining niche reveals BMP signalling inhibition to improve bone disease.Nature communications · 2019Article
- Wnt5a induces and maintains prostate cancer cells dormancy in bone.The Journal of experimental medicine · 2019Article
- Expression of bone morphogenetic protein 6 in non-small cell lung cancer and its significance.Oncology letters · 2019Article
- Alteration of tumor suppressor BMP5 in sporadic colorectal cancer: a genomic and transcriptomic profiling based study.Molecular cancer · 2018Article
- TGF-beta receptor mediated telomerase inhibition, telomere shortening and breast cancer cell senescence.Protein & cell · 2017Article
- Utilizing BMP-2 muteins for treatment of multiple myeloma.PloS one · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previously, bone morphogenetic protein (BMP)-2 and -4 have been shown to inhibit proliferation and induce apoptosis in human myeloma cells. BMP-2 and -4 belong to a subgroup of BMPs using the BMP receptors Alk-3 or -6. In this study, we examined the effects on human myeloma cells of BMP-6 and -7, members of a different BMP subgroup, which mainly utilize Alk-2 as their receptor. All cell lines examined expressed mRNA for the BMP-6 and -7 receptor Alk-2. We did not detect transcripts for the BMP-2 and -4 receptors Alk-3 or Alk-6 in INA-6 and RPMI-8226 cells by RT-PCR. Accordingly, the intracellular signalling molecules Smad-1, -5 and -8 were not phosphorylated by BMP-4 in INA-6 and RPMI-8226 cells. The expression patterns of various BMP receptors in the myeloma cell lines explained the differences in responses to the various BMPs. Alk-2-expressing cell lines responded with growth inhibition and apoptosis to BMP-6 and -7, whereas cell lines lacking both Alk-3 and -6 were resistant to BMP-4. Soluble Alk-3 and -6 were able to neutralize the BMP-4 effects in BMP-4-responsive cell lines. All BMPs reduced viability in more than 70% of purified primary myeloma cell samples. BMPs have intriguing antitumor effects in vitro. Importantly, myeloma cells not responsive to BMP-2 and -4 may still be sensitive to BMP-6 or -7. It is possible that therapeutic use of BMP or BMP analogues could have an impact on both myeloma bone disease and myeloma cell growth.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.